GLG News by Corrective Refractive Laser Surgeons (US)

A new model of the increasing popular Ex-Press Shunt is quite effective in an early study.  Its is quite safe and effective; and simpler substitute for trabeculectomy.  It could be the first line  in the surgical management of glaucoma.

Alcon (ACL) reported positive interim results for their injectable medication for glaucoma.  A single injection of anecortave acetate  resulted in control of IOP at the three month follow up.  This could be a promising medication for IOP control in glaucoma.

The light adjustable lens is a lens implant that is placed in the eye like a tradition intraocular lens during cataract surgery.  The unique difference is that it can be treated with a special light after surgical implant (weeks to months later) to correct any residual refractive errors or to fine...

This was a retrospective clinical study of 21 eyes from 12 patients who identified themselves as being dissatisfied with their visual acuity and were interested either in initial or enhancement refractive surgery in order to improve their acuity. Uncorrected visual acuity was documented in each eye....

Sicrolimus is a novel agent that has a broad range of activities that is entering the Ophthalmic Arena.  Phase I Data has shown its safety profile in treating two large markets: Age Related Macular Degeneration and Diabetic Macular Edema.  Given its success in cardiology, it is a promising...

This study shows that Bausch and Lomb's Zylet is as good and safer than Alcon's Tobradex for the management of Blepharitis.  Blepharitis is a large problem affecting many patients.  This could be a large market opportunity.

Biovitrum reports Phase II results of its new glaucoma medication. Although the mechanism of action of this glaucoma drug is novel and targets the site of disease in glaucoma, its clinical results are very disappointing.  A 10% reduction in intraocular pressure is not enough to make a clinical...

The CATT Trial will prospectively compare lucentis and avastin head to head in the management of Age Related Macular Degeneration.  Lucentis costs 40X more than Avastin for ocular dosing; and many suspect that they both are similiar in efficacy.  If CATT confirms this, it sink Lucentis Sales...

With the recent trends of presbyopic correction , Bausch and Lomb has now entered the arena.

I HAVE BEEN PRODICTING THAT A MAJOR PLAYER WOULD BUY EYEONICS SINCE I FIRST STARTED PLACING THE CRYSTALENS IN MY PATIENTS. THE LENS WORKS BUT NEEDED A PRO AT MARKETING. B& L WILL BENIFIT FROM THIS BUY.